Efficacy and safety of the PI3K delta inhibitor zandelisib (ME-401) on an intermittent schedule (IS) in patients with relapsed/refractory follicular lymphoma (FL) with progression of disease within 24 months of first-line chemoimmunotherapy (POD24) Meeting Abstract
| Authors: | Pagel, J. M.; Reddy, N.; Jagadeesh, D.; Stathis, A.; Asch, A. S.; Salman, H. S.; Kenkre, V. P.; Soumerai, J. D.; Llorin-Sangalang, J.; Gorbatchevsky, I.; Li, J.; Zelenetz, A. D. |
| Abstract Title: | Efficacy and safety of the PI3K delta inhibitor zandelisib (ME-401) on an intermittent schedule (IS) in patients with relapsed/refractory follicular lymphoma (FL) with progression of disease within 24 months of first-line chemoimmunotherapy (POD24) |
| Meeting Title: | 2021 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 39 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2021 Jun 4-8 |
| Meeting Location: | Virtual |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2021-05-20 |
| Language: | English |
| ACCESSION: | WOS:000708120604147 |
| DOI: | 10.1200/JCO.2021.39.15_suppl.7550 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 7550 -- Source: Wos |
